Endocrine Abstracts

Introduction: Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy. For the majority of patients with PTC, the prognosis is very good; however, up to 20% of patients suffer disease recurrence. Currently, the risk stratification for PTC recurrence is based on clinicopathological features which have limited prognostic value. Identification of molecular biomarkers of PTC recurrence such as protooncogene BRAF and miRNAs may help to improve risk-stratifie...

Introduction: Despite low mortality rates of patients with papillary thyroid carcinoma (PTC), disease progression in PTC occurs in up to 20% of patients. Currently, recurrence risk stratification is accomplished by using clinicopathologic factors, despite their limited prognostic value. Some data suggest that patient age at disease onset and primary tumor size may predict the risk of disease progression. Identification of possible associations of traditional clinicopathologica...

Introduction: The sensitivity and specificity of biomarkers which have been used in clinical practice for diagnosis of papillary thyroid carcinoma (PTC) are low. It is essential to develop novel diagnostic biomarkers for PTC.Objective: We aimed to explore the expression levels of miR-222, – 146b, –181b in PTC tissue and plasma samples and to compare with benign thyroid nodules (BTN).Methods: We collected plasma samples ...